FindTrial
Sign In

Use of Itraconazole oral solution in Children with Fungal Infection

The Efficacy and Tolerability of Itraconazole oral solution in Paediatric Dermatophytosis - IPD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/05/019139
Enrollment
30
Registered
2019-05-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B35- Dermatophytosis

Interventions

Intervention1: Drug: Itraconazole Oral Solution Dose 5mg/kg Frequency Once daily Oral administration Duration 4 weks Control Intervention1: Not Applicable: Not Applicable

Sponsors

Dr Ramesh Bhat M
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients age group of 1to12 years with clinical diagnosis of cutaneous dermatophytosis in glabrous skin (Tinea faciei, Tinea corporis and Tinea Cruris). Both boys and girls will be included in the study. Patients /parents/guardians who are consenting to participate in the study. Patients with recurrent and extensive (10% body surface area) Tinea infection will be taken for the study.

Exclusion criteria

Exclusion criteria: • Patients with other pre-existing skin disorders. • Patients/parents/guardians who are not willing to participate in the study.

Design outcomes

Primary

MeasureTime frame
Safety and Efficacy of Oral Itraconasole solution in Paediatric age groupTimepoint: Two weeks and Four weeks—

Secondary

MeasureTime frame
Tolerability and side effects of oral itraconazole solutionTimepoint: 2 weeks and 4 weeks—

Countries

India

Contacts

Public ContactDr Ramesh Bhat M

Father Muller Medical College

rameshderma@gmail.com9845084224

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026